Ovarian cancer recurrence detection study pulled before starting
NCT ID NCT05991752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if a blood test called the ROMA score could find ovarian cancer coming back sooner than the usual CA125 test. The goal was to catch recurrences early, which might allow less invasive surgery and improve quality of life. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Started
-
May 2025
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 18 or over and less than 85 years old * With proven FIGO stage I to IV epithelial ovarian cancer (ovary/tumor/peritoneum) * Women in remission after first-line chemotherapy, with a normal CA125 less than 4 months old at study entry (end of first-line chemotherapy). * Woman having completed chemotherapy at least 6 months previously * Written informed consent * French social security Exclusion Criteria: * Any physical or psychiatric condition that may interfere with the patient's cooperation in data collection * Patient with normal CA125 at initial diagnosis of epithelial ovarian cancer * Patient under guardianship * Patient deprived of liberty
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- Mapping the DNA test that decides who gets PARP inhibitors
- Can inhaled manganese make ovarian cancer immunotherapy hit harder?
- Can a new drug combo keep ovarian cancer from coming back?
- Can a new imaging tracer light up ovarian cancer cells?